ArticleApplied health economics and health policy2022
Avoiding Opportunity Cost Neglect in Cost-Effectiveness Analysis for Health Technology Assessment.
Article in Applied health economics and health policy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- The Opportunity Cost of Funding High-Cost Biologics in the Context of Inequitable Access to the Fundamentals of Care: An External Assessment Group Perspective.PharmacoEconomics · 2026Article
- College of Occupational Therapy - Research Priority 10: What is the cost-effectiveness of Occupational Therapy services? Making the economic case for Occupational Therapy.The British journal of occupational therapy · 2025Article
- Assessing the Value of New Antimicrobials: Evaluations of Cefiderocol and Ceftazidime-Avibactam to Inform Delinked Payments by the NHS in England.Applied health economics and health policy · 2025Article
- Resource allocation in public sector programmes: does the value of a life differ between governmental departments?Cost effectiveness and resource allocation : C/E · 2023Article
- Economic evaluation of self-help group interventions for health in LMICs: a scoping review.Health policy and planning · 2023Article
- Cost-Effectiveness Analysis of Siltuximab for Australian Public Investment in the Rare Condition Idiopathic Multicentric Castleman Disease.PharmacoEconomics - open · 2023Article
- A Model-Based Estimate of the Cost-Effectiveness Threshold in Germany.Applied health economics and health policy · 2023Article
- What are economic costs and when should they be used in health economic studies?Cost effectiveness and resource allocation : C/E · 2023Review
- Supply-Side Cost-Effectiveness Thresholds: Questions for Evidence-Based Policy.Applied health economics and health policy · 2022Review
- The ethics of aggregation in cost-effectiveness analysis or, "on books, bookshelves, and budget impact".Frontiers in health services · 2022Article
Corrections and comments
- Commented on by
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite being a fundamental tenet of economic analysis there is a lack of clarity regarding the relevance of opportunity costs to cost-effectiveness analysis for health technology assessment. We argue that this is due, in part, to the importance of the decision context in understanding the nature of opportunity costs. Taking the example of the National Institute of Health and Care Excellence (NICE) on behalf of the National Health Service (NHS) in England and Wales, we explore the implications of existing discrepancies between policy thresholds and emerging empirical evidence of health opportunity costs. In particular, we consider analysts communicating the results of cost-effectiveness analysis, and recommend that analysts provide analysis according to both the policy threshold and the latest empirical evidence until the discrepancies are better understood or resolved. A number of conceptually related, but distinct, issues are discussed and clarified.
Indexed as
Identifiers
34467474What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.